Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
about
Improved prediction of complex diseases by common genetic markers: state of the art and further perspectivesProstate cancer: ESMO Consensus Conference Guidelines 2012External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer.The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators.The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community settingEvaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome.Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonographyIncorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculatorRisk stratification in prostate cancer screening.Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers.Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study.European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners.PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.Evaluation of PSA-age volume score in predicting prostate cancer in Chinese populationArticle Subject.Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.The Use of Magnetic Resonance Imaging in the Prostate Cancer Primary Diagnostic Pathway: Is It Ready for Primetime?
P2860
Q26770167-69C85CFE-794D-4002-A1E2-03817A57996AQ27022847-17BBDA0E-5B06-4259-9835-FF054C5AA653Q31096808-2C55394A-7352-43AB-8E76-AE737DC941A8Q33672510-91169494-A9EC-4952-86B6-896DBCD22D0CQ33922385-F367CFD4-1690-4AA1-95DF-02463AEA2C72Q35762868-C6072206-23CE-4EED-B1E4-08D6186E919BQ35940811-13B127BC-AF03-4E54-B311-C39EA2B8F055Q36185925-97C43DB4-AB54-4B92-9B37-8995977DE2AAQ36986295-E6B3B8FA-1DCA-480B-85C4-19631FDE01D0Q37001612-B86D30CD-63B2-4B79-B8B8-6107B93A85DAQ37075718-2C850955-F9C4-465B-89B5-8AD9DE340E35Q37113204-295E00E2-40D7-41E0-ABE6-8FB9D465A29FQ37279076-D20FCF37-CD76-48FE-9ECD-49AD55C1DA6BQ38068114-B1168DA1-E398-4AC9-8DA8-097443313E0BQ38268839-4B5E22B8-D939-42BA-9BDC-AC0C246A41F1Q38843182-DE76BA9F-51E6-4F03-A4CE-E7C8F16BAC35Q39003646-97C4D61A-698D-400B-AB5A-4E7B0EBCFE8EQ40034472-1FE66A6D-45C4-4E5C-96EA-12F5FE9CCA68Q40170080-E0FA9A8A-19D1-43C2-BFDE-3A6F9FF57048Q40314717-0DBE740B-3A80-4450-953C-BA3AB79EFA5FQ48500179-1A68FB88-8973-456F-9F31-8D60D111B5D4Q50107743-6D73F734-AF8E-474B-842D-ED35CE3A601BQ57107312-DAA45A45-656B-445E-92BF-534EF4EBE5FD
P2860
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Evaluating the PCPT risk calcu ...... te Biopsy Collaborative Group.
@ast
Evaluating the PCPT risk calcu ...... te Biopsy Collaborative Group.
@en
type
label
Evaluating the PCPT risk calcu ...... te Biopsy Collaborative Group.
@ast
Evaluating the PCPT risk calcu ...... te Biopsy Collaborative Group.
@en
prefLabel
Evaluating the PCPT risk calcu ...... te Biopsy Collaborative Group.
@ast
Evaluating the PCPT risk calcu ...... te Biopsy Collaborative Group.
@en
P2093
P2860
P50
P1476
Evaluating the PCPT risk calcu ...... ate Biopsy Collaborative Group
@en
P2093
Amine Benchikh
Andreas Boeck
Angel M Cronin
Dipen J Parekh
Eric A Klein
Freddie Hamdy
Fritz H Schröder
Gilles Salama
Helmut Klocker
Ian M Thompson
P2860
P2888
P304
P356
10.1007/S00345-011-0818-5
P50
P577
2011-12-31T00:00:00Z